

NEWS RELEASE

HYDERABAD, INDIA (9 May' 2022) -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced audited financial results for the quarter and year ended 31 Mar' 2022. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 9 May' 2022 at Hyderabad.

Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Year ended	
	31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
Revenue from operations	3,638.47	3,915.85	2,591.65	13,202.22	10,097.19
Other Income	1,343.96	92.74	32.98	1,877.88	142.37
Total Income	4,982.43	4,008.60	2,624.63	15,080.10	10,239.56
EBITDA	2,919.65	1,953.02	969.91	7,677.76	4,547.59
EBITDA Margin	58.60%	48.72%	36.95%	50.91%	44.41%
EBIT	2,815.44	1,847.96	886.76	7,286.79	4,231.23
EBIT Margin	56.51%	46.10%	33.79%	48.32%	41.32%
Finance costs	21.89	7.42	18.70	62.31	91.44
Depreciation	104.21	105.06	83.15	390.97	316.36
Taxes	548.90	470.59	223.54	1,643.49	1,053.32
Taxes to PBT	19.65%	25.57%	25.75%	22.75%	25.44%
PAT (Standalone)	2,244.65	1,369.95	644.52	5,580.99	3,086.47
PAT Margin (Standalone)	45.05%	34.18%	24.56%	37.01%	30.14%
Associate Company	-	-	186.66	411.12	537.36
PAT (Consolidated)	916.68	1,600.69	831.16	4,538.05	3,623.42
PAT Margin (Consolidated)	18.40%	39.93%	31.67%	30.09%	35.39%
EPS (Standalore)	8.82	5.38	2.53	21.92	12.12
EPS (Consolidated)	3.60	6.29	3.27	17.83	14.23
Paid up share capital (Re.1/sh)	254.56	254.56	254.56	254.56	254.56

Growth Ratios

	31 Mar 22 to Quarter ended 31 Dec 21	31 Mar 22 to Quarter ended 31 Mar 21	Mar 22 to Year ended 31 Mar 21
Growth in income	24.29%	89.83%	47.27%
Growth in EBIDTA	49.49%	201.02%	68.83%
Growth in EBIT	52.35%	217.50%	72.21%
Growth in PAT Standalone	63.85%	248.27%	80.82%
Growth in PAT Consolidated	-42.73%	10.29%	25.24%

Suven Pharmaceuticals Limited

Operational Profitability	Quarter ending		Year ending	
	31-Mar-22	31-Dec-21	31-Mar-22	31-Mar-21
CDMO Revenue	3,638.47	3,915.85	13,202.22	10,097.19
Adjusted PAT	1,187.85	1,086.19	4,240.42	3,086.47
CDMO PAT/Income	32.65%	27.74%	32.12%	30.57%
Adjusted EBIDTA	1,862.85	1,669.26	6,337.20	4,547.59
CDMO EBIDTA/Income	51.20%	42.63%	48.00%	45.04%
Adjusted EBIT	1,640.19	1,515.02	5,778.61	4,231.23
CDMO EBIT/Income	45.08%	38.69%	43.77%	41.91%

1. The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
2. The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to \$35.00 Mn) in Rising Pharma Holdings, Inc., USA on 13 Dec 2021 and accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P w.e.f 13 Dec 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar 2022.
3. The Board has declared 2nd interim dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 1.00 per equity share (100% of Face value of Rs.1.00), totaling to Rs. 2.00 per equity share (200% of Face value of Rs. 1.00 each) for the financial year 2021-22.
4. Post approval of the Board in the meeting held on 5 April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt. Ltd. an SEZ company engaged in formulations business for USD 20.50 Mn and has become a wholly owned subsidiary of the Company w.e.f. 22 April 2022.
5. The COVID-19 continuous to impact the business and research operations in India.

For more information, please visit: <http://www.suvenpharm.com>

Risk Statement:

Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited